NasdaqGS - Nasdaq Real Time Price USD

Vertex Pharmaceuticals Incorporated (VRTX)

397.48

-0.22

(-0.06%)

At close: 4:00 PM EDT

397.42

-0.06

(-0.02%)

After hours: 6:01 PM EDT

Pioneer Institute study finds IRA discourages non-opioid drug innovation

The IRA adds another hurdle to an already challenging research landscape, according to a study from the Pioneer Institute.

Pharmaceutical Technology 6 hours ago

VRTX
-0.06%
GLDAF
Vertex Announces European Commission Approval for KALYDECO® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older

LONDON, April 26, 2024--Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for the label expansion of KALYDECO® (ivacaftor) for the treatment of infants down to 1 month of age with cystic fibrosis (CF) who have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: R117H, G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R.

Business Wire 7 hours ago

VRTX
-0.06%
The Zacks Analyst Blog Highlights Biogen, Bristol Myers Squibb, Incyte and Vertex Pharmaceuticals

Biogen, Bristol Myers Squibb, Incyte and Vertex Pharmaceuticals are part of the Zacks top Analyst Blog.

Zacks 10 hours ago

VRTX
-0.06%
INCY
+0.98%
CELG-RT
Vertex Pharmaceuticals (VRTX) Falls More Steeply Than Broader Market: What Investors Need to Know

Vertex Pharmaceuticals (VRTX) closed the most recent trading day at $397.70, moving -0.76% from the previous trading session.

Zacks yesterday

VRTX
-0.06%
2 Fantastic Growth Stocks to Buy Right Now

Don't overlook these high-growth businesses.

Motley Fool yesterday

VRTX
-0.06%
PINS
Regeneron to collaborate on gene editing therapies with Doudna-founded Mammoth

Regeneron Pharmaceuticals and Mammoth Biosciences will collaborate to research, develop and commercialize gene editing therapies for multiple diseases, the companies said on Thursday. Mammoth's CRISPR-based gene editing platform and Regeneron's delivery technologies will be used to create disease-modifying medicines that can be delivered to tissues beyond the liver. CRISPR, discovered by Jennifer Doudna and CRISPR Therapeutics co-founder Emmanuelle Charpentier, uses molecular "scissors" to trim faulty parts of genes that can then be disabled or replaced with new strands of normal DNA.

Reuters yesterday

REGN
-0.84%
CRSP
+0.34%
VRTX
-0.06%
Missed Out on Novo Nordisk? 2 Healthcare Stocks With Big Catalysts on the Horizon.

Good news could be just around the corner for two drugmakers not named Novo Nordisk.

Motley Fool 2 days ago

NVO

VRTX
-0.06%
VKTX
Health Care Roundup: Market Talk

Read about Vertex Pharmaceuticals, cannabis sales, Novartis and more in the latest Market Talks covering the Health Care sector.

The Wall Street Journal 3 days ago

VRTX
-0.06%
VERA
Vertex (VRTX), TreeFrog Sign Deal for Diabetes Cell Therapies

Vertex (VRTX) signs a collaboration agreement with TreeFrog to utilize the latter's C-Stem technology in order to optimize the production of its T1D cell therapies.

Zacks 3 days ago

VRTX
-0.06%
FGEN

ANVS
Vertex Pharmaceuticals Just Made 2 Big Moves. Is the Stock a Buy?

Vertex is broadening its portfolio.

Motley Fool 3 days ago

VRTX
-0.06%
VERTEX AND TREEFROG THERAPEUTICS ANNOUNCE LICENSING AGREEMENT AND COLLABORATION TO OPTIMIZE PRODUCTION OF VERTEX'S CELL THERAPIES FOR TYPE 1 DIABETES

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and TreeFrog Therapeutics today announced that Vertex has obtained an exclusive license to TreeFrog's proprietary cell manufacturing technology, C-StemTM, to optimize production of Vertex's cell therapies for type 1 diabetes (T1D). TreeFrog and Vertex will collaborate to scale-up TreeFrog's process to produce and amplify cells for Vertex's T1D therapies.

CNW Group 3 days ago

VRTX
-0.06%
10 Best Performing Biotech ETFs in 2024

In this article, we discuss the 10 best performing biotech ETFs in 2024. If you want to skip our detailed introduction to the biotech industry and just want to take a look at some more ETFs, go directly to the 5 Best Performing Biotech ETFs in 2024. Biotechnology is a challenging field, not ideal for […]

Insider Monkey 4 days ago

LLY
+1.19%
EXAS

NBIX
Making Sense of Amazon CEO Andy Jassy's Latest Letter

And that's just part of the interesting news for investors to dig into.

Motley Fool 4 days ago

AMZN

NVDA

^GSPC
If You'd Invested $10,000 in Vertex Pharmaceuticals 5 Years Ago, Here's How Much You'd Have Today

Could Vertex's growth story continue?

Motley Fool 4 days ago

VRTX
-0.06%
^GSPC
Looking for Once-in-a-Generation Investment Opportunities? Here Are 3 Magnificent Stocks to Buy Right Now

These stocks could be near major inflection points.

Motley Fool 4 days ago

VRTX
-0.06%
OXY-WS

PATH
2 Everlasting Big Pharma Stocks to Buy Today and Hold Forever

These stocks probably won't be getting much cheaper.

Motley Fool 6 days ago

VRTX
-0.06%
NVO
3 Relatively Safe Growth Stocks You Can Buy and Hold

Low risk and high-reward potential? These stocks could offer both.

Motley Fool 6 days ago

VRTX
-0.06%
LLY
+1.19%
NVO
3 Biotech Stocks Set to Double by 2028

Biotech stocks offer the possibility of groundbreaking medical advancements alongside the potential for explosive growth. While the sector carries inherent risks, a select group of biotech companies possesses the potential to deliver substantial returns in the coming years. It is no surprise that investors continue to turn to this sector as advancements in technology strengthen its growth prospects. From revolutionary gene therapies to cancer research, the possibilities are endless. Furthermore,

InvestorPlace 6 days ago

NVO

VRTX
-0.06%
Vertex Pharmaceuticals (VRTX) Gains As Market Dips: What You Should Know

In the most recent trading session, Vertex Pharmaceuticals (VRTX) closed at $394.28, indicating a +0.2% shift from the previous trading day.

Zacks 7 days ago

VRTX
-0.06%
Vertex (VRTX) Begins Rolling NDA Filing for Acute Pain Drug

Vertex (VRTX) begins rolling NDA submission for its investigational non-opioid candidate, suzetrigine, for acute pain management. The submission is expected to be completed in second-quarter 2024.

Zacks 7 days ago

VRTX
-0.06%
ANVS

Performance Overview

Return	VRTX	S&P 500
YTD	-2.31%	+6.92%
1-Year	+19.75%	+25.26%
3-Year	+82.41%	+22.00%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Vertex Pharmaceuticals Incorporated (VRTX)

Pioneer Institute study finds IRA discourages non-opioid drug innovation

Vertex Announces European Commission Approval for KALYDECO® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older

The Zacks Analyst Blog Highlights Biogen, Bristol Myers Squibb, Incyte and Vertex Pharmaceuticals

Vertex Pharmaceuticals (VRTX) Falls More Steeply Than Broader Market: What Investors Need to Know

2 Fantastic Growth Stocks to Buy Right Now

Regeneron to collaborate on gene editing therapies with Doudna-founded Mammoth

Missed Out on Novo Nordisk? 2 Healthcare Stocks With Big Catalysts on the Horizon.

Health Care Roundup: Market Talk

Vertex (VRTX), TreeFrog Sign Deal for Diabetes Cell Therapies

Vertex Pharmaceuticals Just Made 2 Big Moves. Is the Stock a Buy?

VERTEX AND TREEFROG THERAPEUTICS ANNOUNCE LICENSING AGREEMENT AND COLLABORATION TO OPTIMIZE PRODUCTION OF VERTEX'S CELL THERAPIES FOR TYPE 1 DIABETES

10 Best Performing Biotech ETFs in 2024

Making Sense of Amazon CEO Andy Jassy's Latest Letter

If You'd Invested $10,000 in Vertex Pharmaceuticals 5 Years Ago, Here's How Much You'd Have Today

Looking for Once-in-a-Generation Investment Opportunities? Here Are 3 Magnificent Stocks to Buy Right Now

2 Everlasting Big Pharma Stocks to Buy Today and Hold Forever

3 Relatively Safe Growth Stocks You Can Buy and Hold

3 Biotech Stocks Set to Double by 2028

Vertex Pharmaceuticals (VRTX) Gains As Market Dips: What You Should Know

Vertex (VRTX) Begins Rolling NDA Filing for Acute Pain Drug

Performance Overview